We are excited to collaborate with Biogen on litifilimab,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “Royalty Pharma offers tailored, win-win funding solutions for ...

In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on Ascendis Pharma (ASND – Research Report), with a price target of $175.00. The company’s shares closed ...

This is the second successful treatment in a donkey, demonstrating the potential of Innocan's Liposomal CBD injection for human and veterinary use HERZLIYA, Israel and CALGARY, AB, Feb. 10, 2025 ...

As one of the world’s biggest contributors to climate change, pharma is morally obliged to adapt its processes and operations – and doing so will open up new opportunities for growth.

The rise of artificial intelligence (AI), digitalisation, wider adoption of tools for marketing automation, and numerous other technologies have significantly reshaped the world of pharma for the ...

A Ugandan doctor vaccinates the contact of a patient who tested positive during the launch of the vaccination for the Sudan strain of the Ebola virus with a trial vaccine at the Mulago Guest House ...

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ("HOPE ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Elite's management will host a live confere Elite Pharmaceuticals ( (ELTP) ) has issued an update. Elite Pharmaceuticals announced the launch of its generic version of Vyvanse® (Lisdexamfetamine ...

2025 The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat movement-related symptoms of Parkinson's disease, the drugmaker said on Tuesday.

Infinity Pharmaceuticals Inc. 0.00% $90.76 ...

Rights Aug 02, 2023 Aug 02, 2023 Feb 08, 2023 Rights ratio: 5 share for every 46 held at a price of Rs 81.0 ...